Overall, the apparent dual function of TLR9 to act in immune cells (to promote antitumor immunity) or in cancer cells (to promote tumor growth and progression) will likely govern the outcomes of therapeutic TLR9 stimulation in various cancer models, including prostate cancer. This evidence concerns the gene TLR9 and prostate carcinoma.